SER-287 (SERES-101 study)
SERES-101 is a Phase 1b clinical study evaluating the safety and efficacy of SER-287 versus placebo, in adults with mild-to-moderate Ulcerative Colitis (UC). This study is called a Phase 1b study because it was primarily intended to assess the safety and tolerability of SER-287 when taken by adults, but it will also attempt to identify preliminary signs of efficacy in patients with UC. The full name of the clinical study is: “A Phase 1b Multiple Dose Study to Evaluate the Safety, Tolerability, and Microbiome Dynamics of SER-287 in Subjects with Mild-to-Moderate Ulcerative Colitis.”
Seres reported positive results of its Phase 1b study of SER-287 in patients with UC. Future development in other forms of IBD are under consideration.
About Ulcerative Colitis
In several previously reported studies, some UC patients with mild-to-moderate disease administered bacteria through fecal microbiota transplant from a healthy donor experienced improvements in their UC symptoms, suggesting that changes in the bacteria may contribute to this clinical response.
SERES-101 Clinical Trial
Learn more about our Phase 1b Trial >
Enrollment is now complete. Please check back.
SERES Therapeutics Pipeline
Learn more about Seres Therapeutics Pipeline >